Capital stacks and blueprints

Documented real-world structure

Volume guarantee platform

A documented structure: capital layers, funding and repayment flows, risk allocation and limitations.

Last reviewed
Related chapter
Philanthropy as Amplifier

Label: Documented real-world structure. Source: MedAccess, 2025 Annual Review and Accounts (case 3).

Problem addressed. A manufacturer will not supply a health product at a lower price without a volume commitment; a procurer cannot commit to volume without a price.

Layers and roles

LayerCapital or commitmentProviderRole
Guarantee capitalUSD 170 millionBritish International InvestmentStands behind the guarantees; the balance sheet.
Counter-guaranteeUp to EUR 52 million, covering up to 30 percent of losses on eligible African guaranteesEuropean Investment Bank (2025)Shares the balance-sheet risk.
Operating grantsAmounts not publicFCDO, Gates Foundation, Wellcome (since 2021)Fund scoping, negotiation, execution, and monitoring of agreements.
FeesNot publicCounterpartiesCover partnership costs.

Funding flows. No capital flows to the manufacturer or procurer at signing. MedAccess signs a volume guarantee: if purchases fall below an agreed floor, MedAccess pays the manufacturer the shortfall.

Repayment flows. None in the conventional sense. If volumes are met, the guarantee expires unused. Fees cover operating costs; surpluses are reinvested.

Risk allocation. MedAccess (backed by BII, and partly by EIB) carries volume risk. Manufacturer is protected against the downside of a lower price. Procurer gets the lower price without a volume commitment.

What the philanthropic contribution enables. The grants fund the work of structuring. Without them, the balance sheet would sit idle. The Gates Foundation, Wellcome, and FCDO are paying for the expertise that turns capital into agreements.

Governance and accountability. Annual accounts; disclosure statement; impact case studies; an impact method that projects "additional" outcomes against a no-intervention scenario, with MedAccess stating it claims contribution rather than credit.

Reported scale (end 2025). 18 transactions; USD 872 million in sales enabled; USD 228 million in procurer savings; net exposure around USD 128 million; guarantee liability around USD 1.6 million. No calls or realised losses reported.

Conditions under which the structure may not work. A demand shock that triggers multiple calls at once. A manufacturer that uses the guaranteed floor to under-invest in distribution. A procurer that would have bought at the lower price anyway. The model has not yet been stress-tested by a large call.

Sources

  1. Philanthropy as Amplifier — free book and foreword
  2. MedAccess — 2025 Annual Review and Accounts

Educational material, not investment, legal or tax advice. Reported figures and review dates reflect the cited sources and editorial review; they are not live data.

MAD. Entrepreneurs Making A Difference

A capital platform backing growth-stage companies applying new science and engineering to restore the systems humanity depends on.

MAD VenturesLevel 3, 180 George StreetSydney NSW 2000, Australia

hello@mad.vc

The MAD Briefing

Capital, founders, and system change for the next cycle. Direct to your inbox.

Acknowledgement of Country. MAD acknowledges the Traditional Owners of the lands on which we live and work, the Gadigal people of the Eora Nation. We pay our respects to Elders past and present, and extend that respect to all Aboriginal and Torres Strait Islander people.

Important Information

Information for eligible Australian wholesale clients and US accredited investors only. The information on this website is general information only and does not constitute financial, tax, legal, investment, or other professional advice. It does not constitute an offer of securities for sale or an invitation to purchase or subscribe for securities. Any investment opportunity referenced is offered privately and only to wholesale clients as defined under sections 761G and 708(8) of the Corporations Act 2001 (Cth), and to eligible US accredited investors under applicable US law, under separate offer documentation. Investments are speculative, high risk, and capital is at risk. Target returns are not guaranteed and past performance is not a reliable indicator of future performance. MAD Fund 1 is intended to be registered as an Early Stage Venture Capital Limited Partnership (ESVCLP); registration is currently conditional and the tax concessions described depend on unconditional registration and continuing compliance. Legislation may change. Prospective investors should obtain their own independent financial, legal and tax advice before making any investment decision. Nothing on this website should be relied on as a substitute for the Information Memorandum and Partnership Deed, available on request to eligible investors via the Investor Room.

© 2026 MAD Management Pty Ltd. All rights reserved.